Swedish Orphan Biovitrum AB and Bioverativ Inc. today announces that new data from their extended half-life therapies, Alprolix® (eftrenonacog alfa)([Coagulation Factor IX (Recombinant), Fc Fusion Protein] and Elocta® (efmoroctocog alfa), marketed as ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein]) in the United States, Japan and Canada, will be presented at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress, taking place in Berlin, Germany, from July 8-13, 2017.


Share this story, choose your platform!